Abpro Corporation (ABP) Stock Analysis & Investment Frameworks
Abpro Corporation (ABP) stock analysis on Invetso. Review Abpro Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Abpro Corporation Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Abpro Corporation Key Financial Metrics
- Market Cap: $1.06M
- Revenue: $183000.00
- ROE: 27.59%
- ROIC: 23.28%
- Dividend Yield: N/A
About Abpro Corporation
Abpro Holdings, Inc. is a biotechnology firm dedicated to creating antibody-based treatments for patients suffering from conditions in immuno-oncology, ophthalmology, and autoimmunity. A key element of their strategy is the proprietary DiversImmune platform, which aims to resolve a significant hurdle in the antibody therapeutics sector. Their primary investigational drug candidates include ABP-100, designed to target breast, gastric, and colorectal cancers, and ABP-201, intended for the treatment of vascular diseases affecting the eye. The company has established strategic alliances with Abpro Bio Co. Ltd and NJCTTQ. Originally known as Abpro Corporation, the company officially changed its name to Abpro Holdings, Inc. in November 2024. Incorporated in 2004, Abpro Holdings, Inc. operates from its headquarters in Woburn, Massachusetts.